Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* The subject must have had her most recent surgical and - if available - histological, diagnosis of pelvic endometriosis up to 10 years before screening.~* The subject has moderate to severe endometriosis-associated pain during the screening period.~* The subject has regular menstrual cycles.~* The subject has a BMI ≥ 18 kg/m2 at the screening visit.~Key Exclusion Criteria:~* The subject is pregnant or breast feeding or is planning a pregnancy within the duration of the treatment period of the study.~* The subject had an interventional surgery for endometriosis performed within a period of 60 days before screening.~* The subject did not respond to prior treatment with gonadotropin releasing hormone (GnRH) agonists or GnRH antagonists for endometriosis.~* The subject has a history of, or known osteoporosis or other metabolic bone disease.~* The subject has chronic pelvic pain that is not caused by endometriosis and requires chronic analgesic / therapy, or that would interfere with the assessment of endometriosis related pain.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- OBE2109 50 mg (Type: EXPERIMENTAL): None
- OBE2109 75mg fixed dose (FD) (Type: EXPERIMENTAL): None
- OBE2109 75mg titrated dose (TD) (Type: EXPERIMENTAL): None
- OBE2109 100mg (Type: EXPERIMENTAL): None
- OBE2109 200 mg (Type: EXPERIMENTAL): None
- Placebo / OBE2109 100mg (Type: PLACEBO_COMPARATOR): Participants received placebo for the first 12 weeks and were then crossed-over to active treatment with OBE2109 100mg for a further 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).